Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | DAO | P14920 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | DDO | Q99489 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370573 | 0.75 | FLT3 (1.00) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL31277139 | 0.75 | FLT3 (0.77) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL31060426 | 0.75 | FLT3 (1.00) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL374022 | 0.74 | RAB9A (0.74) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL29631691 | 0.74 | RAB9A (0.74) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL248620 | 0.73 | BRD4 (1.00) | FLT3KDM4EDAOHPGDHSD17B10 | |
| SCHEMBL4460778 | 0.73 | DAO (0.60) | FLT3KDM4EDAOMAPTHPGD | |
| Methane SCHEMBL22343918 | 0.73 | FLT3 (0.96) | FLT3KDM4EDAOMAPTHPGD | |
| Indole-2-Carboxylic Acid SCHEMBL1935 | 0.73 | KDM4E (1.00) | FLT3KDM4EDAOMAPTHPGD | |
| Indole-2-Carboxylic Acid SCHEMBL29395165 | 0.73 | KDM4E (1.00) | FLT3KDM4EDAOMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190221750-A1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-07-18 | — | — | US | claimed |
| US-20190185457-A1 | HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2019-06-20 | — | — | US | claimed |
| US-20190016745-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2019-01-17 | — | — | US | claimed |
| EP-3400231-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | Technion Research & Development Foundation Limited (IL) | 2018-11-14 | — | — | EP | claimed |
| EP-3344641-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | Eloxx Pharmaceuticals Ltd. (IL) | 2018-07-11 | — | — | EP | claimed |
| WO-2017118967-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-07-13 | — | — | WO | claimed |
| WO-2017037719-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2017-03-09 | — | — | WO | claimed |
| WO-2015087094-A1 | NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-06-18 | — | — | WO | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | claimed |
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | claimed |
| US-6956039-B2 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | claimed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | claimed |
| US-6576628-B1 | Matrix metalloprotease inhibitors; arthritis, corneal ulcers, arteriosclerosis | ROCHE DIAGNOSTICS GMBH (DE) | 2003-06-10 | — | — | US | claimed |
| EP-0860435-A1 | Pyridazin-3-one derivatives and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-08-26 | — | — | EP | claimed |
| EP-0749419-A1 | OXIME DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER AG (DE) | 1996-12-27 | — | — | EP | claimed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | claimed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | claimed |
| WO-1995024383-A1 | OXIME DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-09-14 | — | — | WO | claimed |
| EP-0127876-B1 | PROCESS FOR PREPARING PHOSPHONIC-ACID ESTERS, AND PHOSPHONIC ACID DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-08-12 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185457-A1 | HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | CRY1, NAP1L1, CYP1A1 | FLT3 2126/4885KDM4E 3581/4885DAO 1665/4885 |
| US-20190016745-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | ALPI, MGAM, AASDHPPT | FLT3 403/4885KDM4E 3744/4885DAO 438/4885 |
| US-20190221750-A1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | CRY1, CRY2, MCM4 | FLT3 3382/4885KDM4E 3296/4885DAO 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.